Johanna Lempainen

Johanna Lempainen

Auto-generated profile, based on publicly available information

Johanna Lempainen

Immunogenetics Laboratory, Institute of Biomedicine, University of Turku, Turku, Finland

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2015 in Journal of Autoimmunity
Verified
Journal Article
Closed access
JLJohanna Lempainen
Johanna Lempainen
ALAntti-Pekka Laine
Antti-Pekka Laine
AHAnna Hammais
Anna Hammais
JTJorma Toppari
Jorma Toppari
OSOlli Simell
Olli Simell
JIJorma Ilonen
Jorma Ilonen

1 September 2009 in Journal of Autoimmunity
Verified
Journal Article
Closed access
JLJohanna Lempainen
Johanna Lempainen
OVOuti Vaarala
Outi Vaarala
MMMiia Mäkelä
Miia Mäkelä
RVRiitta Veijola
Riitta Veijola
OSOlli Simell
Olli Simell
JIJorma Ilonen
Jorma Ilonen

15 September 2011 in Diabetes/Metabolism Research and Reviews
Verified
Journal Article
Closed access
PDF file
JLJ. Lempainen
J. Lempainen
STS. Tauriainen
S. Tauriainen
OVO. Vaarala
O. Vaarala
MMM. Mäkelä
M. Mäkelä
HHH. Honkanen
H. Honkanen
JIJorma Ilonen
Jorma Ilonen

18 October 2018 in Pediatric Diabetes
Verified
Journal Article
Closed access
PDF file
IEIlse Ekman
Ilse Ekman
TVTytti Vuorinen
Tytti Vuorinen
MKMikael Knip
Mikael Knip
RVRiitta Veijola
Riitta Veijola
JTJorma Toppari
Jorma Toppari
JLJohanna Lempainen
Johanna Lempainen

1 April 2017 in Journal of Infection
Verified
Journal Article
Open access
LILauri Ivaska
Lauri Ivaska
JNJussi Niemelä
Jussi Niemelä
JLJohanna Lempainen
Johanna Lempainen
RÖRiikka Österback
Riikka Österback
MWMatti Waris
Matti Waris
VPVille Peltola
Ville Peltola
Besides group A streptococcus (GAS), microbial causes of pharyngitis in children are not well known. We aimed to document the viral and bacterial aetiology of pharyngitis and to assess the pathogenic role of viruses by determining the myxovirus resistance protein A (MxA) in the blood as a marker of interferon response. In this prospective observational study, throat swabs and blood samples were collected from children (age 1-16 years) presenting to the emergency department with febrile pharyngitis. Microbial cause was sought by bacterial culture, polymerase chain reaction, and serology. Blood MxA level was determined. A potential pathogen was detected in 88% of 83 patients: GAS alone in 10%, GAS and viruses in 13%, group C or G streptococci alone in 2% and together with viruses in 3%, and viruses alone in 59% of cases. Enteroviruses, rhinoviruses, and adenoviruses were the most frequently detected viruses. Blood MxA levels were higher in children with viral (880 [245-1250] μg/L; median [IQR]) or concomitant GAS-viral (340 [150-710] μg/L) than in those with sole GAS (105 [80-160] μg/L) infections. Detection of respiratory viruses simultaneously with elevated blood MxA levels supports the causative role of viruses in the majority of children with pharyngitis.

14 March 2012 in Diabetes
Verified
Journal Article
Open access
PDF file
JLJohanna Lempainen
Johanna Lempainen
RHRobert Hermann
Robert Hermann
RVRiitta Veijola
Riitta Veijola
OSOlli Simell
Olli Simell
MKMikael Knip
Mikael Knip
JIJorma Ilonen
Jorma Ilonen
We set out to analyze the role of two major non-HLA gene polymorphisms associated with type 1 diabetes (T1D), PTPN22 1858C/T and insulin gene INS−23 A/T in progression to clinical T1D after the appearance of β-cell autoimmunity. The study population comprised 249 children with HLA-associated T1D susceptibility. All subjects were persistently positive for at least one of the T1D-associated biochemically defined autoantibodies (insulin autoantibody, GAD antibody, or IA-2 antibody), and 136 subjects presented with T1D over a median follow-up of 4.3 years (range 0.0–12.5) after the appearance of the first autoantibody. The PTPN22 1858T allele was strongly associated with progression to T1D after the appearance of the first biochemically defined β-cell autoantibody (hazard ratio 1.68 [95% CI 1.09–2.60], P = 0.02 Cox regression analysis, multivariate test), and the effect remained similar when analyzed after the appearance of the second autoantibody (P = 0.013), whereas INS−23 HphI AA genotype was not associated with progression to clinical diabetes after the appearance of the first or second autoantibody (P = 0.38 and P = 0.88, respectively). The effect of the INS risk genotype seems to be limited to the induction and early phases of β-cell autoimmunity, but the PTPN22 1858T allele instead affects the initiation and late progression phase of diabetes-associated autoimmunity.